Fate Therapeutics Inc. inked a multiyear, global collaboration worth up to $3 billion with Janssen Biotech Inc., which calls for the latter to contribute antigen binding domains for up to four tumor-associated targets.
Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in the March 10, 2020, edition of Cancer Research.
Dragonfly Therapeutics Inc., of Cambridge, Mass., has expanded a strategic collaboration with Merck & Co. Inc. on the development of natural killer (NK) cell engager immunotherapies for oncology to add infectious disease and immune disorders. For $47.5 million up front, it's granting Merck the option to license exclusive rights to candidates developed using its TriNKET cell technology platform.
Immatics Biotechnologies GmbH, of Tuebingen, Germany, and Arya Sciences Acquisition Corp. plan to merge as Immatics NV. Immatics will receive gross proceeds of up to $252 million at closing, which is expected in the second quarter of 2020.
PERTH, Australia – Sydney-based Immutep Ltd. reported positive interim data for its phase II basket trial in non-small-cell lung cancer (NSCLC) and head and neck squamous cell carcinoma for its lead immunotherapy in combination with Merck & Co. Inc.’s anti-PD-1 therapy, Keytruda (pembrolizumab).
LONDON – Researchers have discovered a T-cell receptor (TCR) that is both capable of targeting a range of solid tumors and independent of human leukocyte (HLA) type, opening up the prospect of developing a universal anticancer T-cell therapy.
Unveiled by Oxfordshire, U.K.-based Immunocore Ltd. at the November meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Md., were encouraging new findings from the phase I/II study with tebentafusp (also known as IMC-gp100), a bispecific protein in the pivotal works for metastatic uveal melanoma (MUM). The results showed a correlation between treatment-induced immune response and improvement in overall survival (OS) and tumor shrinkage in advanced uveal as well as cutaneous melanoma.
BEIJING – Chinese T-cell immunotherapy specialist Immunotech Biopharm Ltd., of Beijing, has become the seventh pre-revenue biotech on the waiting list to go public on the Hong Kong Stock Exchange (HKEX). In an application filed this week, the specific amount was not disclosed, but company said much of the proceeds are expected to advance its lead candidate targeting liver cancer.
It seems likely that this year’s Nobel Prize for physiology or medicine will be remembered by many people who normally forget about it before the physics prize is even announced. One of the three prize winners, Ralph Steinman, passed away last Friday. The Nobel Prizes are not usually awarded posthumously; the Nobel Prize website, in fact, states that such awards are “not possible,” and so it is unclear whether Steinman is, indeed, a Nobelist or not. According to a report by the Associated Press, committee members didn't know Steinman was dead when they chose him as a winner and are...
This week’s report of remissions in three advanced leukemia patients after immunotherapy has generated quite a lot of excitement in the media – which, in turn, has led to some backlash amongst the twitterati and in the blogosphere, noting that two complete remissions plus a partial one don’t make a blockbuster. Or anything, really, that will be broadly useful within the next few years. Mainly, when I look at these controversies, I am grateful that I write for such a smart audience. If you are reading this blog, chances are that you work in the biopharmaceutical industry – and if...